• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Lumizyme (alglucosidase alfa)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – July 2012

 

Summary View

 

ADVERSE REACTIONS

Postmarketing Experience
  • abdominal pain, nephrotic syndrome and proteinuria, as observed events to the package insert